Return to Clinical Trials

Intravenous Administration In Combination With Paclitaxel And Carboplatin - United Kingdom

In July 2009, Oncolytics announced it had completed patient enrolment in the Phase II component of its Phase I/II U.K. trial using intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin.

The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN® when administered in combination with paclitaxel and carboplatin. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

See related press releases and documents:

Phase I/II Trial Of Oncolytic Reovirus (Reolysin®) In Combination With Carboplatin/Paclitaxel In Patients With Advanced Solid Cancers

July 2, 2009 - Oncolytics Biotech® Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN® and Paclitaxel/Carboplatin Head and Neck Cancer Trial

March 20, 2009 - Oncolytics Biotech® Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN® and Paclitaxel/Carboplatin Trial

November 3, 2008 - Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN® and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting

October 23, 2008 - Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN® and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting

April 9, 2008 - Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN® and Carboplatin/Paclitaxel Trial

May 29, 2007 - Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN®/Paclitaxel and Carboplatin Trial

December 22, 2006 - Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN® in Combination with Paclitaxel and Carboplatin